Latest news

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay...

PlaqueTec wins MedTech Company of the Year at the Cambridge Independent Science and Technology Awards 2024

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has...

PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by...

PlaqueTec closes $8 million equity financing

The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support...

PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood

Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary...

Profiling plaque to guide treatment of coronary artery disease

Published in Cardiovascular News, Dr Stephen Hoole, Chief Investigator of our BIOPATTERN trial and Consultant Cardiologist at Royal...

PlaqueTec recruits first ten patients in BIOPATTERN trial

PlaqueTec receives the UK’s MHRA approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

PlaqueTec presents ePoster at 14th Annual ECS Conference

What is the relationship between protein concentration at site of coronary atheroma and fibrous cap thickness?